PharmaGap Inc. is a development stage company, principally engaged in drug development and out-licensing of drug compounds. It is a biotechnology company with the main focus on designing and developing therapeutic drugs for the treatment of cancer and other human diseases associated with the human Protein Kinase C enzyme (PKC). Using its drug development platform, the Company is developing a pipeline of compounds targeting PKC. PKC is expressed in abnormal levels in many types of cancer and other diseases, such as diabetes. As of December 31, 2007, the Company’s lead drug compound, PhGa1, was in the pre-clinical testing stage, and had shown in vitro and in vivo efficacy in selected cancer types.
(Source: ARS)
